CN106133521A - 用于治疗异质肿瘤的病患特异性的免疫疗法 - Google Patents

用于治疗异质肿瘤的病患特异性的免疫疗法 Download PDF

Info

Publication number
CN106133521A
CN106133521A CN201480065876.2A CN201480065876A CN106133521A CN 106133521 A CN106133521 A CN 106133521A CN 201480065876 A CN201480065876 A CN 201480065876A CN 106133521 A CN106133521 A CN 106133521A
Authority
CN
China
Prior art keywords
antibody
cell
sufferer
clone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480065876.2A
Other languages
English (en)
Chinese (zh)
Inventor
雅维兰·沙利叶
宜兰·赫斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Su Rui Technology Co Ltd
Original Assignee
Su Rui Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Su Rui Technology Co Ltd filed Critical Su Rui Technology Co Ltd
Publication of CN106133521A publication Critical patent/CN106133521A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480065876.2A 2013-10-02 2014-10-02 用于治疗异质肿瘤的病患特异性的免疫疗法 Pending CN106133521A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885511P 2013-10-02 2013-10-02
US61/885,511 2013-10-02
PCT/IL2014/050870 WO2015049688A2 (en) 2013-10-02 2014-10-02 Patient-specific immunotherapy for treating heterogeneous tumors

Publications (1)

Publication Number Publication Date
CN106133521A true CN106133521A (zh) 2016-11-16

Family

ID=52779242

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480065876.2A Pending CN106133521A (zh) 2013-10-02 2014-10-02 用于治疗异质肿瘤的病患特异性的免疫疗法
CN201580064980.4A Pending CN107207605A (zh) 2013-10-02 2015-04-08 用于治疗异质肿瘤的病患特异性的免疫疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580064980.4A Pending CN107207605A (zh) 2013-10-02 2015-04-08 用于治疗异质肿瘤的病患特异性的免疫疗法

Country Status (5)

Country Link
US (2) US20160237163A1 (https=)
EP (2) EP3052933B1 (https=)
JP (2) JP2017502983A (https=)
CN (2) CN106133521A (https=)
WO (2) WO2015049688A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207605A (zh) * 2013-10-02 2017-09-26 苏瑞科技有限公司 用于治疗异质肿瘤的病患特异性的免疫疗法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113391A2 (en) * 2012-02-02 2013-08-08 Brainlab Ag Method for determining an infusion parameter
WO2016187711A1 (en) * 2015-05-22 2016-12-01 Csts Health Care Inc. Biomarker-driven molecularly targeted combination therapies based on knowledge representation pathway analysis
EP3298524A4 (en) 2015-05-22 2019-03-20 CSTS Health Care Inc. THERMODYNAMIC MEASURES ON PROTEIN-PROTEIN INTERACTION NETWORKS FOR CANCER THERAPY
AU2016339022B2 (en) * 2015-10-12 2020-09-10 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CA3026236C (en) * 2016-06-03 2021-01-26 Samsung Life Public Welfare Foundation Method for screening antibody using patient-derived tumor spheroids
US12072337B2 (en) 2017-05-30 2024-08-27 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
WO2019156254A1 (ja) * 2018-02-09 2019-08-15 アクシオンリサーチ株式会社 検査対象の複雑系の状態を推定するシステム
CN113597305B (zh) * 2019-03-15 2025-03-04 舒万诺知识产权公司 使用因果模型制造生物药物
US20220268762A1 (en) * 2019-07-28 2022-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
JP7438693B2 (ja) 2019-09-02 2024-02-27 キヤノンメディカルシステムズ株式会社 診療支援装置
IL292346B2 (en) 2019-11-05 2025-02-01 Apeel Tech Inc Predicting contamination in plant products
JP2024527371A (ja) * 2021-07-08 2024-07-24 オウロテック インコーポレイテッド 処置の有効性予測システム及び方法
CN115153829B (zh) * 2022-06-23 2026-03-31 中国人民解放军空军军医大学 基于活性组织电阻抗信息非均匀重构的电脉冲消融模型精度优化方法
TWI909458B (zh) * 2024-05-17 2025-12-21 國防醫學大學 一種自體免疫疾病用藥預估方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054171A2 (en) * 2000-12-06 2002-07-11 Biosentients, Inc. System, method, software architecture and business model for an intelligent object based information technology platform
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
US20070213961A1 (en) * 2000-10-19 2007-09-13 Optimata System and Methods for Optimized Drug Delivery and Progression of Diseased and Normal Cells
US20090117111A1 (en) * 2005-11-01 2009-05-07 Sharon Lea Aukerman Uses of anti-cd40 antibodies
US20110130850A1 (en) * 2009-05-29 2011-06-02 Aspen Technology, Inc. Apparatus and method for model quality estimation and model adaptation in multivariable process control
US20110300156A1 (en) * 2008-12-09 2011-12-08 Genmab A/S Human antibodies against tissue factor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101646470B (zh) * 2007-03-27 2012-08-22 皇家飞利浦电子股份有限公司 基于由加速度传感器测量的患者活动状态的给药
EP2549399A1 (en) * 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
EP2844675B1 (en) * 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
CN104470843B (zh) 2012-07-18 2016-07-20 三菱电机株式会社 电梯装置
US9725768B2 (en) * 2012-08-31 2017-08-08 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines
WO2014126198A1 (ja) * 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
ES2662598T3 (es) * 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213961A1 (en) * 2000-10-19 2007-09-13 Optimata System and Methods for Optimized Drug Delivery and Progression of Diseased and Normal Cells
WO2002054171A2 (en) * 2000-12-06 2002-07-11 Biosentients, Inc. System, method, software architecture and business model for an intelligent object based information technology platform
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
US20090117111A1 (en) * 2005-11-01 2009-05-07 Sharon Lea Aukerman Uses of anti-cd40 antibodies
US20110300156A1 (en) * 2008-12-09 2011-12-08 Genmab A/S Human antibodies against tissue factor
US20110130850A1 (en) * 2009-05-29 2011-06-02 Aspen Technology, Inc. Apparatus and method for model quality estimation and model adaptation in multivariable process control

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207605A (zh) * 2013-10-02 2017-09-26 苏瑞科技有限公司 用于治疗异质肿瘤的病患特异性的免疫疗法

Also Published As

Publication number Publication date
WO2015049688A3 (en) 2015-06-11
CN107207605A (zh) 2017-09-26
EP3201844A1 (en) 2017-08-09
WO2016051398A1 (en) 2016-04-07
JP2018500275A (ja) 2018-01-11
EP3052933A2 (en) 2016-08-10
WO2016051398A8 (en) 2016-06-02
US20160237163A1 (en) 2016-08-18
EP3052933A4 (en) 2017-05-17
US20180009901A1 (en) 2018-01-11
EP3201844A4 (en) 2018-05-02
JP2017502983A (ja) 2017-01-26
WO2015049688A2 (en) 2015-04-09
EP3052933B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
CN106133521A (zh) 用于治疗异质肿瘤的病患特异性的免疫疗法
Katz et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial
TWI695013B (zh) 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
CN109862915A (zh) 针对信号调控蛋白α的抗体和使用方法
CN109069626A (zh) 抗-vista(b7h5)抗体
JP7826449B2 (ja) サイトカイン放出症候群を予測する多変量モデル
JP2008502597A (ja) Ｎｋ型ｌｄｇｌのような免疫増殖性障害を処置するための組成物および方法
JP2017502983A5 (https=)
CN109476752A (zh) 抗-pd-1抗体与抗-cd30抗体的组合在淋巴瘤治疗中的用途
US20240025994A1 (en) Anti-lag-3 monoclonal antibody and antigen binding fragment thereof, and use thereof
CA3177717A1 (en) Compositions and methods for treating cancer
CN113747944A (zh) 用抗psma/cd3抗体治疗前列腺癌的方法
UA124732C2 (uk) Введення біспецифічної конструкції, що зв'язується з сd33 і сd3, для використання в способі лікування мієлоїдного лейкозу
WO2021257552A1 (en) Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
JP2021531766A (ja) Ｃｄ２２６アゴニスト抗体
Yang et al. Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors
JP2022529970A (ja) 抗ｐｓｍａ／ｃｄ３抗体で腎癌を治療する方法
CN104479022A (zh) 抗s-腺苷同型半胱氨酸单克隆抗体301、其杂交瘤、组合物、胶体金试纸、试剂盒及用途
Kruger et al. Challenges in clinical trial design for T cell‐based cancer immunotherapy
Stacy Therapeutic MAbs: saving lives and making billions: monoclonal antibodies spur a lucrative new period in biomedicine.
Tyagi et al. Hybridoma technique in pharmaceutical science
Mahdavi et al. Production and characterization of new anti-HER2 monoclonal antibodies
US20210095018A1 (en) Anti-tetraspanin 33 agents and compositions and methods for making and using the same
Trier et al. Production of antibodies to peptide targets using Hybridoma Technology
Jacobs Myeloma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161116

WD01 Invention patent application deemed withdrawn after publication